

## INCIDENCE OF ADVERSE DRUG REACTION AMONG THE T.B PATIENTS TREATED UNDER DOTS REGIMEN IN NORTH INDIA

Ashif Ali Hassan<sup>1</sup>, Ranjan Kumar<sup>2</sup>, Amit Kumar<sup>3</sup>, Shakir Alam<sup>4</sup>

<sup>1</sup>Assistant Professor, Department of Microbiology, JLNMC, Bhagalpur, Bihar, India.

<sup>2</sup>Tutor, Department of Microbiology, JLNMC, Bhagalpur, Bihar, India.

<sup>3</sup>Associate Professor, Department of Microbiology, JLNMC, Bhagalpur, Bihar, India.

<sup>4</sup>Tutor, Department of Microbiology, JLNMC, Bhagalpur, Bihar, India.

Received : 19/10/2023  
Received in revised form : 29/12/2023  
Accepted : 15/01/2024

**Keywords:**  
Adverse Drug Reaction, T.B Patients,  
Dots Regimen.

Corresponding Author:  
**Dr. Ranjan Kumar,**  
Email: ranjandmch@gmail.com.

DOI: 10.47009/jamp.2024.6.1.287

Source of Support: Nil,  
Conflict of Interest: None declared

*Int J Acad Med Pharm*  
2024; 6 (1); 1438-1440



### Abstract

**Background:** The present observational study was undertaken to demonstrate the extent of adverse effects of anti-tuberculosis drug used in category 1st category 2nd and category 3rd treatment regimens under Directly Observed Treatment Short Course (DOTS) and impact of these adverse drug re- action on the outcome of treatment. **Materials and Methods:** This present study was carried out at the Department of Microbiology cum DOTS centre in JLNMC BHagalpur Bihar, a Tertiary care hospital for the period of 1 year. After obtaining the permission from the ethical committee 150 patient between the ages of 5 and 80 years with tuberculosis, who were treated under DOTS in category 1<sup>st</sup>, 2nd, and 3rd Were included in the study. Individuals with multi drug resistant tuberculosis (MDR) and extended drug resistant tuberculosis (XDR), previously existing severe disease, history of recurrent psychotic or major affective disorder, alcohol or drug abuse within the previous year or current cardiac, renal or hepatic dysfunction, women who were pregnant, lactating, or planning to become pregnant were excluded from study. Two consecutive sputum smear examination and culture were performed for the diagnosis of pulmonary tuberculosis. Further investigation like X-ray chest PA view was also done for the Confirmation of pulmonary tuberculosis. The clinical details of the patient were documented in a standard Performa. **Result:** A total of 150 patients with tuberculosis were examined to assess the development of ADRS after the treatment. Out of 150 patients 85 were come under category 1, 25 in category 2 and 40 in category 3. Out of 150 patients 68(46%) were developed ADR. In females' higher incidence (45.7%) of adverse drug reactions were observed. Among different categories the higher number of adverse drug reactions were observed in category 2. **Conclusion:** Female as well as patient with category two is more prone to develop ADR. So physician should take proper care while treating these patients to prevent gastrointestinal discomfort which is more common.

## INTRODUCTION

Tuberculosis remains a major social and economical burden in the developing country like India. According to the World Health Organization (WHO), one-third of the world's population have been exposed to the tuberculosis pathogen.<sup>[1]</sup> Treated tuberculosis has a mortality rate of less than 5% in developing countries.<sup>[2]</sup> Adverse Drug Reactions (ADR) have potential to further complicate the issue of poor treatment compliance. To overcome these issues, Government of India in association with WHO and Swedish International Development Agency (SIDA), launched Revised National Tuberculosis Control Programme

(RNTCP).<sup>[3]</sup> This is well known that all drugs are able to produce adverse drug reactions and when we prescribe drugs to the patient, we take a risk of inducing adverse drug reactions.

The incidence of developing adverse drug reactions are 10-25% documented in different clinical settings and they are more common with multiple drug therapy for a long duration. The present observational study was undertaken to demonstrate the extent of adverse effects of anti-tuberculosis drug used in category 1st category 2nd and category 3rd, treatment regimens under Directly Observed Treatment Short Course (DOTS) and impact of these adverse drug re- action on the outcome of treatment.

## MATERIALS AND METHODS

This present study was carried out at the Department of Microbiology cum DOTS centre in JLNMCBhagalpur Bihar, a Tertiary care hospital for the period of 1 year. After obtaining the permission from the ethical committee 150 patient between the ages of 5 and 80 years with tuberculosis, who were treated under DOTS in category 1st, 2nd, and 3rd Were included in the study. Individuals with multi drug resistant tuberculosis (MDR) and extended drug resistant tuberculosis (XDR), previously existing severe disease, history of recurrent psychotic or major affective disorder, alcohol or drug abuse within the previous year or current cardiac, renal or hepatic dysfunction, women who were pregnant, lactating, or planning to become pregnant were excluded from study.

Two consecutive sputum smear examination and culture were performed for the diagnosis of pulmonary tuberculosis. Further investigation like X-ray chest PA view was also done for the Confirmation of pulmonary tuberculosis. The clinical details of the patient were documented in a standard Performa. Duration of treatment was categorised as per following groups; 6months for category 1st and 3rd and 8 months for category 2nd. Patients were clinically evaluated and examined for their response on every month and advised to visit any time if develops any severe problems during treatment were documented. The presence of symptoms suggestive of adverse drug reactions and as well as their severity like mild, moderate and severe were documented.

### Statistical Analysis

Statistical analysis was based on intent to treat (ITT) population, which included all patients who received various regimens of DOTS under RNTCP.

## RESULTS

A total of 150 patients with tuberculosis were examined to assess the development of ADRS after the treatment. Out of 150 patients 85 were come under category 1, 25 in category 2 and 40 in category 3. Of the 150 patient 125 were male while 25 were females with the age group of 05-20, 20-35, 35-50, and 50-80. Under category1; 51(60.61%) were male and 34(40.83%) were female. Under category 2; 15(19.27%) were male and 10(26.03%) were female and under category 3; 31(15.95%) were male and 17(29.68%) were female. In category 1; maximum number of patients was with age group 20-35 years, followed by age group 05-20years, age group 35-50 years and with age group 50-80 years respectively. In category 2 maximum numbers of patients were with age group 20-35 years, followed by 50-80 years, 35-50 years and 05-20 years respectively. In category 3 maximum numbers of patients were with age group 20-35 years, followed by 05-20 years, 35-50 years and 50-80 years respectively. Out of 150 patients 68(46%) were developed ADR. In fe-males higher incidence (45.7%) of adverse drug reactions were observed. Among different categories the higher number of adverse drug reactions were observed in category 2. The details of adverse drug reactions among the different age groups, time periods of the treatment and patient's socioeconomically group are summarized in table 1. In all the categories the maximum numbers of incidence of ADR were noted in Gastro Intestinal Tract (GIT). Different types of ADRs developed among the categories are sum-marized in table.

**Table 1:**

Type of ADRs	Cat.185	%	Cat 225	%	Cat 340	%
Mild gastritis	29	36.12	4	20	4	12.17
Sever gas-tritis	12	12.31	2	6.83	4	3.90
CNS	6	5.21	2		4	6.45
PNS	6	5.21	2	6.83	4	6.45
Hepatitis	8	6.79	3	6.83	4	6.45
Renal	1	0.68	2	6.83	4	6.45
Itching	4	4.31	2	6.83	4	6.45
Otological	3	0.68	2	6.83	2	3.23
Ocular	4	4.31	2	6.83	4	6.45
Joint Pain	9	1.67	2	6.83	4	6.45
Psychiatric	5	4.72	2	6.83	2	3.23

On analysis of the outcome of the patient, we found 35% patients with ADRs were recovered with proper antibiotic therapy however the mortality rate was significantly low1.35.

## DISCUSSION

Compliance with anti-TB medication is essential to effective management. Two strategies to ensure compliance are DOTS and fixed dose combination (FDC).<sup>[4]</sup> Our studyfully applied on DOTS strategy.

Generally, these drugs are well tolerated<sup>5</sup>, may be associated with unwanted effects of different origin. In our study, the incidence of ADRs was 46%. However, several studies from other part of the world reported higher incidence of ADR among their study population.<sup>[6,7]</sup> In contradiction to those findings, our study reported a lower rate of ADRs,

However lower incidence of ADRs also reported from different part of the world,<sup>[8,9]</sup> which is lesser than our findings. This discrepancy may be due to geographical and physical factor of the population. We are not the first to observe that females are at higher risk of developing ADRs. Several other studies also reported the higher prevalence of ADR among the female patient.<sup>[10,11]</sup> The reason behind that they pass through different life stages like pregnancy, menarche etc., which modify the drug response.<sup>[12]</sup> Based on those findings we can suggest that female patients need special precautions while prescribing antituberculous drugs.

In the present study the incidence of ADR were significantly higher in gastrointestinal tract however incidence of ADR were low in excretory tract which indicates that gastrointestinal tract is more affected due to ADR in compare to other system.<sup>[13]</sup> We also observed 1 in 4 patients with ADR were recovered with proper antibiotic treatment however mortality rate was significantly lower in the study population. On analysis of the category based distribution we observed in category 1, 1 in 5 patients were female, in category 2, 1 in 4 patients were female and in category 3, 1 in 3 patients were female. On category based distribution we also observed in category 1, 1 in 3 patients were with age group 05-20 years, 1 in 4 with age group 20-35 years, 1 in 5 patients with age group 35-50 years and 1 in 10 with age group 50-80 years. In category 2, 1 in 9 patients were with age group 05-20 years, 1 in 4 with age group 20-35 years, 1 in 8 patients with age group 35-50 years and 1 in 7 with age group 50-80 years. In category 3, 1 in 4 patients were with age group 05-20 years, 1 in 3 with age group 20-35 years, 1 in 6 patients with age group 35-50 years and 1 in 19 with age group 50-80 years.

## CONCLUSION

Female as well as patient with category two is more prone to develop ADR. So physician should take proper care while treating these patients to prevent gastrointestinal discomfort which is more common.

## REFERENCES

1. National Institute of Allergy and Infectious Diseases (NIAID). [2] 26 October 2005. Retrieved on 3 October 2006 [www.niaid.nih.gov/](http://www.niaid.nih.gov/)
2. World Health Organization (WHO). Tuberculosis Fact Sheet N°104 Global and regional incidence. March 2006, Retrieved on 6 October 2006. [/www.who.int/](http://www.who.int/)
3. RNTCP at glance 2006 [www.tbcindia.nic.in/rntcp.html](http://www.tbcindia.nic.in/rntcp.html)
4. Raviglione MC, O'Brien RJ (2004). "Tuberculosis", in Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, Isselbacher KJeds.: Harrison's Principles of Internal Medicine, 16th ed., McGraw-Hill Professional, 953–66.
5. World Health Organization (WHO). Tuberculosis Fact Sheet N°104 Global and regional incidence. March 2006, Retrieved on 6 October 2006. [/www.who.int/](http://www.who.int/)
6. Chukanov VI, Kaminskaia GO and Livchane E. Frequency and pattern of adverse reactions due to treatment of patients with pulmonary tuberculosis with antitubercular reserve drugs. *Probl TuberkBolezniLegk.*2004;(10):6-10.
7. P A Routledge, M S O'Mahony, and K W Woodhouse. Adverse drug reactions in elderly patients; *Br J ClinPharmacol.*2004; 57(2):121–126.
8. MishinViu, Vasil'eva IA, Makieva VG, Kuz'mina NV, Frequency, pattern, and diagnosis of adverse reactions in patients with pulmonary tuberculosis during chemotherapy with leading drugs. *Probl TuberkBolezniLegk.*2003;(7):24-29
9. [www.who.int/tb/publications/global\\_report/gtbr12\\_main.pdf](http://www.who.int/tb/publications/global_report/gtbr12_main.pdf)
10. Ormerod L. P., Horsfield N. (1996). Frequency and type of reactions to antituberculosis drugs: observations in routine treatment. *Tuber Lung Dis.*2016; 77(1):37-42.
11. Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. *Am J Resp Crit Care Med.*2021;167(11):1472–77
12. Kumarjit Sinha, Izora Trudy R Marak, W Asoka Singh. Adverse drug reactions in tuberculosis patients due to directly observed treatment strategy therapy. *The Journal of Association of Chest Physicians* 2022; 2(1):50-53.
13. Dhingra VK, Rajpal S, Aggarwal N, Aggarwaln JK, Shadab K and Jain SK. Adverse drug reactionsobserved during DOTS. *J. Commun. Dis.* 2023;36(4): 251- 259.